• Home
  • NEW DAY MEDICINE
  • 10 (84) 2025
  • 150 -10 (84) 2025 - Kholikova A.O., Abidova D.Kh. - "MRI CHARACTERISTICS OF PATIENTS WITH INACTIVE PITUITARY MACROADENOMAS WITH SECONDARY EMPTY SELLA SYNDROME DEPENDING ON THE TREATMENT RECEIVED"

150 -10 (84) 2025 - Kholikova A.O., Abidova D.Kh. - "MRI CHARACTERISTICS OF PATIENTS WITH INACTIVE PITUITARY MACROADENOMAS WITH SECONDARY EMPTY SELLA SYNDROME DEPENDING ON THE TREATMENT RECEIVED"

"MRI CHARACTERISTICS OF PATIENTS WITH INACTIVE PITUITARY MACROADENOMAS WITH SECONDARY EMPTY SELLA SYNDROME DEPENDING ON THE TREATMENT RECEIVED"

Kholikova A.O. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y.Kh. Turakulov, Department of Neuroendocrinology Republic of Uzbekistan

Abidova D.Kh. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y.Kh. Turakulov, Department of Neuroendocrinology Republic of Uzbekistan

Resume

The purpose of the study was to study the MRI characteristics of patients with non-functional pituitary macroadenomas (NFPA) with secondary empty sella syndrome (SEES)_ depending on the treatment received Material and research methods. A total of 35 patients with macro-NfPA and secondary SEES who applied to the outpatient clinic in 2023 were examined. Of these, 15 (42.9%) were men, 20 (57.1%) were women. Research methods included: 1) general clinical (study of endocrine, neurological status), 2) instrumental (perimetry for all colors, fundus, visual acuity, ECG, CT/MRI of the sella turcica and adrenal glands, ultrasound of internal and genital organs and etc.), 4) biochemical and hormonal blood tests Research results. on MRI of the pituitary gland, a double fundus was found in 8 (100%)/13(87%)/10/(83.3%) cases, asymmetry of the sellar fundus was observed in 8 (100%)/10 (66.7%)/10(83.3%), erosion sellar fundus - in 8 (100%)/8 (53.3%)/9(75%), expansion of the third ventricle - 5 (62.5%)/5 (33.3%)/8(66.7%), observations in 1, 2, respectively and 3 groups. Recurrent tumor growth after TAH occurred in 5 patients in group 2 of patients. Conclusions. 1. Among patients with macroNFPA, the most pronounced changes characterizing the development of secondary empty sella syndrome were identified in group 1 – those subjected to combined treatment. 2. The most pathognomonic MRI sign in secondary SEES is asymmetry and erosion of the sellar fundus 3. Four months after combined treatment, changes on MRI in group 1 of patients were still most pronounced compared to other groups.

Key words: NFPAs, MRI of the pituitary gland, secondary empty sella syndrome.

First page

848

Last page

853

For citation:Kholikova A.O., Abidova D.Kh. - "MRI CHARACTERISTICS OF PATIENTS WITH INACTIVE PITUITARY MACROADENOMAS WITH SECONDARY EMPTY SELLA SYNDROME DEPENDING ON THE TREATMENT RECEIVED"//New Day in Medicine 10(84)2025 848-853 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

  1. Petersenn S, Quabbe HJ, Schöfl C, Stalla GK, von Werder K, Buchfelder M. The rational use of pituitary stimulation tests. // Dtsch Arztebl Int. 2010;107:437–443
  2. Chiloiro S, Giampietro A, Bianchi A, et al. Diagnosis of endocrine disease: primary empty sella: a comprehensive review. // Eur J Endocrinol. 2017;177:R275–R285
  3. Guitelman M, Garcia Basavilbaso N, Vitale M, et al. Primary empty sella (PES): a review of 175 cases. // Pituitary. 2013;16:270–274
  4. Giustina A, Aimaretti G, Bondanelli M, et al. Primary empty sella: why and when to 4. investigate hypothalamic-pituitary function. // J Endocrinol Invest. 2010;33:343–346
  5. Auer MK, Stieg MR, Crispin A, Sievers C, Stalla GK, Kopczak A. Primary Empty Sella Syndrome and the Prevalence of Hormonal Dysregulation. // Dtsch Arztebl Int. 2018 Feb 16;115(7):99-105. doi: 10.3238/arztebl.2018.0099.
  6. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. // Cell. 2001;104(6):849–859. doi: 10.1016/S0092-8674(01)00282-3.
  7. Lloyd R. V., Kovacs K., Young W. F., Jr., et al. Pituitary tumours: introduction. In: DeLellis R. A., Lloyd R. V., Heitz P. U., Eng C., editors. //Tumours of the Pituitary, Chapter 1. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, Paris: World Hearth Organization Classification of Tumours. IARC Press; 2004. pp. 10–13
  8. Mccormack A. I., Wass J. A. H., Grossman A. B. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. // European Journal of Clinical Investigation. 2011;41(10):1133–1148. doi: 10.1111/j.1365-2362.2011.02520.x.
  9. Wang S, Li B, Ding C, Xiao D, Wei L. A novel "total pituitary hormone index" as an indicator of postoperative pituitary function in patients undergoing resection of pituitary adenomas. // Oncotarget. 2017 Mar 7;8(45):79111-79125. doi: 10.18632/oncotarget.15978.
  10. Niu J, Zhang S, Ma S, Diao J, Zhou W, Tian J, Zang Y, Jia W. Preoperative prediction of cavernous sinus invasion by pituitary adenomas using a radiomics method based on magnetic resonance images. // Eur Radiol. 2019 Mar;29(3):1625-1634. doi: 10.1007/s00330-018-5725-3.

    file

    download